Análise das dosagens e concentrações séricas da ciclosporina A em cães da raça Golden Retriever normais ou afetados pela distrofia muscular / Analyses of dosages and blood concentration of cyclosporin A on norrmal Golden Retriever dogs or Golden Retriever with muscular dystrophy

A distrofia muscular dos cães Golden Retriever (GRMD), uma miopatia degenerativa causada pela ausência da distrofina é geneticamente homóloga à distrofia muscular de Duchenne que acomete humanos, portanto, estes cães são considerados modelos experimentais para estudos em terapia celular. Seu sucesso depende da imunossupressão adequada. A ciclosporina A (CsA) é indicada para tal e a monitorização de suas concentrações sangüíneas e efeitos adversos são essenciais para viabilizar a terapia. Foram estudados cães GRMD, e normais da mesma raça, submetidos a terapia com CsA, associada, nos GRMD, ao transplante de células tronco. Foram avaliados as concentrações sangüíneas do fármaco através de amostras coletadas a cada dois ou três dias e analisadas pelo método do imunoensaio por fluorescência (FPIA). Como resultado observamos que as concentrações de CsA oscilaram muito, em seis dos oito animais. Concluímos que as doses variam individualmente sendo de maior importância avaliar a concentração do fármaco no sangue e sua viabilização no uso da terapia celular

The muscular dystrophy of Golden Retriever (GRMD) is a degenerative miopaty caused by the absence of dystrophy and it is genetically homologue of the Duchenne muscular dystrophy in humans, so, these dogs are considerably experimental models for studies on cellular therapy. Their successful depends of the adequate immunosuppression. Cyclosporin A (CsA) is indicated for that and the monitoring of the blood concentration and adverse effects are essential to viabilise the therapy. It was studied GRMD dogs, and normal dogs from the same breed, submitted for therapy with CsA, associated, on GRMD, of cell transplantation. It was evaluated blood concentration of the drug, between two or tree days using the method of FPIA. In our results we found that the CsA blood concentrations oscillated too much on six than eight of our animals. We concluded that the doses varieties Braz. J. vet. Res. anim. Sci., São Paulo, v. 45, n. 2, p. 131-137, 2008 individually and the correct dosage as to important as the evaluation of the blood concentration of the drug and became viable for cell therapy

Analysis of Monitoring Results on Cyclosporin A Plasma Concentration in Bone Marrow Transplantation Recipients / 中国药房

OBJECTIVE:To observe the efficacy and safety of the effective blood concentration of cyclosporin A in patients after bone marrow transplantation.METHODS:By fluorescence polarization immunoassay(FPIA),the whole blood trough concentration of CsA in 14 patients after undergoing bone marrow transplantation was monitored for 216 times in total from day 1 to day 466,and the monitoring results were analyzed.RESULTS:The effective blood concentrations of CsA in patients with chronic myelocytic leukemia(CML),acute non lymphocytic leukemia(AML),acute lymphoblastic leukemia (ALL),Mediterranean disease(THAL),and pancytopenia were(50～450) ng?mL~(-1),(100～450) ng?mL~(-1),(100～350) ng?mL~(-1)(200～500) ng?mL~(-1),and(250～500) ng?mL~(-1),respectively.Rejection reaction appeared in 7 cases after bone marrow transplantation,with whole blood trough concentration of CsA ranged from 67.4 ng?mL~(-1) to 189.34 ng?mL_(-1) (125.44?39.56 ng?mL~(-1)on average).Adverse drug reaction appeared in 3 cases,with trough concentration of CsA ranged from 412.5 ng?mL~(-1) to 548.62 ng?mL~(-1)(481.39?68.08 ng?mL~(-1) on average).CONCLUSION:Timely monitoring of plasma concentration of CsA and modifying of the dosage regimen can avoid the occurrence of rejection reaction and adverse drug reaction,which is of great significance for patients' medication safety and efficacy.

Comparison of High Performance Liquid Chromatography and Fluorescence Polarization Immunoassay for Determination of Total Homocysteine in Human Plasma / 대한임상병리학회지

BACKGROUND: It was purposed to estimate correlation between fluorescence polarization immunoassay (FPIA) and high performance liquid chromatography (HPLC), and precision of individual methods. It was also objected to describe distribution of plasma total homocysteine in Korean adults. METHODS: The subjects were 100 adults admitted to Inha University Hospital during the month of October, 1998. The total plasma homocysteine concentration was measured by FPIA (IMx analyzer, Abbott Laboratories, IL, USA) and by HPLC (ACCLAIM Biogenic Amines Testing System, Bio-Rad Laboratories, CA, USA) using Bio-Rad Homocysteine. RESULTS: Plasma homocysteine levels (mean+/-SD) from Korean healthy adults by FPIA and HPLC were 9.75+/-3.80micromol/L, 7.72+/-3.36micromol/L, respectively. Plasma homocysteine levels according to sex by FPIA were 11.79micromol/L for male, 7.71micromol/L for female, and those by HPLC were 9.47micro mol/L for male, 5.98micromol/L for female, respectively. Intra-assay coefficient variations (CVs) of low, medium, and high concentration by FPIA are 1.83%, 0.47%, and 1.66%, and those by HPLC are 5.53%, 5.37%, and 4.56%, respectively. Inter-assay CVs of low, medium, and high concentration by FPIA are 2.28%, 1.44%, and 1.29%, and by HPLC are 7.23%, 5.54%, and 4.95%, respectively. CONCLUSION: Plasma homocysteine levels from male were significantly higher than female in Korean. Plasma homocysteine levels were increased according to increment of age. FPIA was more convenient, automatic, rapid, and reproducible than HPLC and also excellently correlated with HPLC. It is concluded that FPIA will potentially benefit for quantifying homocysteine in clinical laboratories.

Study on CsA Therapeutic Window Concentration in Renal Transplant Recipients / 中国药房

OBJECTIVE:To establish an optimal therapeutic window concentration of CsA trough levels in renal transplant recipients on triple immunosuppressants regimen METHODS:A total 1 874 samples from 268 renal transplant recipients were measured by fluorescence polarization immunoassay(FPIA) According to the duration after operation and clinical diagnoses ,the whole blood CsA trough levels were compared among subgroups RESULTS:The optimal therapeutic window concentration of CsA was 300～400?g/L(within 1 month after operation),250～350?g/L(2nd～3rd month),150～250?g/L(4th～6th month),100～200?g/L(7th～12th month)and 100～150?g/L(more than 12 months) CONCLUSION:The above mentioned therapeutic window concentratin of CsA trough levels was ideal for renal transplant recipients with no marked acute toxic effects and rejection reaction